On October 8, 2010, the U.S. Food and Drug Administration (FDA) asked Abbott Laboratories to voluntarily withdraw from the U.S. market, its weight loss drug Meridia (sibutramine) because of clinical trial data indicating an increased risk of cardiovascular adverse events, including heart attack and stroke, in the studied population. Abbott has agreed to voluntarily stop marketing of Meridia in the United States.
FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine)
Questions and Answers: FDA Recommends Against the Continued Use of Meridia (sibutramine)
Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia[ARCHIVED]
Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review[ARCHIVED]
Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride)[ARCHIVED]